{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for clindamycin root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2007
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2000)
Source URL:
First approved in 2000
Source:
21 CFR 333E
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 1993
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 1955
Source:
Clorpactin WCS-90 by United-Guardian, Inc.
Source URL:
Class:
POLYMER
Sodium hexametaphosphate is a food additive and a softening agent for water and detergents. Sodium hexametaphosphate can also be found in leathers, pigments, and personal care products such as toothpaste. A significant use for sodium hexametaphosphate is as a deflocculant in the production of clay-based ceramic particles. It is also used as a dispersing agent to break down clay and other soil types. Sodium hexametaphosphate hydrolyzes in aqueous solution, particularly under acidic conditions, to sodium trimetaphosphate and sodium orthophosphate.
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2015
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
BLA125812
(2024)
Source URL:
First approved in 2024
Source:
BLA125812
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Investigational
Source:
NCT01414153: Phase 2 Interventional Completed Exudative Age-related Macular Degeneration
(2012)
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
M022
(2024)
Source URL:
First approved in 2024
Source:
M022
Source URL:
Class:
CONCEPT
Status:
US Approved Rx
(2024)
Source:
NDA217900
(2024)
Source URL:
First approved in 2024
Source:
NDA217900
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
